Symmcora® Long-term Bidirectional Barbed Suture for Anastomosis in Patients Undergoing Robot Assisted Radical Prostatectomy
Launched by AESCULAP AG · Sep 25, 2023
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a special type of stitch called the Symmcora® Long-term bidirectional barbed suture, which is used during surgery for prostate cancer. Specifically, the trial aims to see if this new suture can help doctors complete a key step in the surgery—connecting the bladder to the urethra—more quickly than with other methods, while keeping the risk of complications low.
To participate in this study, men aged 18 and older who are scheduled for elective robotic-assisted surgery for prostate cancer may be eligible. However, those with certain conditions, like a history of steroid use, previous prostate surgeries, or allergies to the suture material, cannot join. If you take part, you can expect to have your surgery as planned with this new type of suture being used, while researchers monitor the time it takes to complete the surgery and any potential complications. This trial is currently recruiting participants, and your involvement could contribute to improving surgical techniques for prostate cancer treatment.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Male patients undergoing an elective robotic assisted radical prostatectomy
- • Written informed consent
- • Age ≥ 18years
- Exclusion Criteria:
- • Emergency surgery
- • History of chronic steroid use
- • Previous prostatic surgery
- • Previous radiotherapy or brachytherapy
- • Patients with hypersensitivity or allergy to the suture material.
- • Participation in another study
- • Non-compliant patient (dementia etc)
About Aesculap Ag
Aesculap AG is a prominent global medical device manufacturer specializing in surgical instruments, implants, and innovative healthcare solutions. With a rich history rooted in excellence and innovation, Aesculap AG is dedicated to advancing surgical practices through cutting-edge technology and a commitment to improving patient outcomes. The company collaborates with healthcare professionals and institutions to conduct clinical trials that evaluate the safety and efficacy of its products, ensuring that they meet the highest standards of quality and performance. Through its rigorous research and development initiatives, Aesculap AG aims to contribute significantly to the field of medicine and enhance the standards of surgical care worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Madrid, , Spain
Móstoles, Madrid, Spain
Patients applied
Trial Officials
Dr. Miguel Sánchez Encinas, Dr.
Principal Investigator
Hospital Universitario Rey Juan Carlos
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported